These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 83968)
41. Serum-mediated protection of neoplastic cells from inhibition by lymphocytes immune to their tumor-specific antigens. Hellström I; Hellström KE; Evans CA; Heppner GH; Pierce GE; Yang JP Proc Natl Acad Sci U S A; 1969 Feb; 62(2):362-8. PubMed ID: 5256215 [TBL] [Abstract][Full Text] [Related]
42. Tumor-secific immunity to chemically induced tumors. Evidence for immunologic specificity and shared antigenicity in lymphocyte responses to soluble tumor antigens. Frbes JT; Nakaw Y; Smith RT J Exp Med; 1975 May; 141(5):1181-200. PubMed ID: 47896 [TBL] [Abstract][Full Text] [Related]
43. Dependence of initiation of an innocent bystander cytotoxicity reaction on the association of viral antigens and tumor cell membranes in mice. Lopez DM; Lopez PF; Parks WP; Paul RD J Natl Cancer Inst; 1986 May; 76(5):923-31. PubMed ID: 2871214 [TBL] [Abstract][Full Text] [Related]
44. Serologically defined, unique surface antigen on a mouse mammary adenocarcinoma. Kuzumaki N; Klein G J Natl Cancer Inst; 1979 Mar; 62(3):619-22. PubMed ID: 84092 [TBL] [Abstract][Full Text] [Related]
45. Serum factors in mammary neoplasia: enhancement and antagonism of spleen cell activity in vitro detected by different methods of serum factor assay. Blair PB; Lane MA J Immunol; 1974 Feb; 112(2):439-53. PubMed ID: 4813898 [No Abstract] [Full Text] [Related]
46. A micro-colony-inhibition method for quantitation of tumor immunity. Haskill JS J Natl Cancer Inst; 1973 Nov; 51(5):1581-8. PubMed ID: 4762935 [No Abstract] [Full Text] [Related]
47. Secondary in vitro generation of cytolytic T-lymphocytes (CTL's) in the murine sarcoma virus system. Virus-specific CTL induction across the H-2 barrier. Collavo D; Parenti A; Biasi G; Chieco-Bianchi L; Colombatti A J Natl Cancer Inst; 1978 Sep; 61(3):885-90. PubMed ID: 80457 [TBL] [Abstract][Full Text] [Related]
48. Cellular cytotoxicity in tumor-bearing mice after transfer of normal or tumor-sensitized lymphoid cells. Fisher B; Wolmark N; Saffer EA J Natl Cancer Inst; 1980 Dec; 65(6):1303-5. PubMed ID: 6933275 [TBL] [Abstract][Full Text] [Related]
49. Modulation of the immunosuppressive effects of splenic macrophages in Fischer rats bearing adenocarcinoma 13762. Bonaventure J; Nigam VN; Brailovsky CA Cancer Immunol Immunother; 1985; 20(2):167-74. PubMed ID: 3849979 [TBL] [Abstract][Full Text] [Related]
50. Cell-mediated immunity to antigens associated with murine sarcoma virus-induced tumors: augmentation of cytolytic T lymphocyte activity by successive specific and nonspecific stimulation in vitro. Ryser JE; Cerottini JC; Brunner KT Eur J Immunol; 1979 Mar; 9(3):179-84. PubMed ID: 221224 [TBL] [Abstract][Full Text] [Related]
51. Lymphokine-activated tumor inhibition in vivo. I. The local administration of interleukin 2 triggers nonreactive lymphocytes from tumor-bearing mice to inhibit tumor growth. Forni G; Giovarelli M; Santoni A J Immunol; 1985 Feb; 134(2):1305-11. PubMed ID: 3871210 [TBL] [Abstract][Full Text] [Related]
52. Kinetics of responses to tumor antigens and mouse mammary tumor virus in BALB/cCrgl and BALB/cfC3H mice. Lopez DM; Sigel MM; Charyulu VL J Natl Cancer Inst; 1981 Jan; 66(1):191-6. PubMed ID: 6256573 [TBL] [Abstract][Full Text] [Related]
53. In vitro detection of immune responses to MTV-induced mammary tumors: activity of spleen cell preparations from both MTV-free and MTV-infected mice. Blair PB; Lane MA; Yagi MJ J Immunol; 1974 Feb; 112(2):693-705. PubMed ID: 4360546 [No Abstract] [Full Text] [Related]
54. Multicellular spheroids: a new model target for in vitro studies of immunity to solid tumor allografts. Sutherland RM; MacDonald HR; Howell RL J Natl Cancer Inst; 1977 Jun; 58(6):1849-53. PubMed ID: 140943 [TBL] [Abstract][Full Text] [Related]
55. Phenotypes associated with tumor rejection mediated by cyclophosphamide and syngeneic tumor-sensitized T lymphocytes: potential mechanisms of action. Evans R Int J Cancer; 1984 Mar; 33(3):381-8. PubMed ID: 6607893 [TBL] [Abstract][Full Text] [Related]
56. Pregnancy-induced cytotoxicity of splenocytes against mammary tumor cells in rats. Chakravarty PK; Ghosh SK; Sinha DK Oncology; 1991; 48(5):425-30. PubMed ID: 1745492 [TBL] [Abstract][Full Text] [Related]
57. The immune response of the mouse to lymphocytic choriomeningitis virus. V. High numbers of cytolytic T lymphocytes are generated in the spleen during acute infection. Moskophidis D; Assmann-Wischer U; Simon MM; Lehmann-Grube F Eur J Immunol; 1987 Jul; 17(7):937-42. PubMed ID: 2886344 [TBL] [Abstract][Full Text] [Related]
58. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells. Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295 [TBL] [Abstract][Full Text] [Related]
59. Secondary specific immune response in vitro to MSV tumor cells. Senik A; Hebrero FP; Levy JP Int J Cancer; 1975 Dec; 16(6):946-59. PubMed ID: 53210 [TBL] [Abstract][Full Text] [Related]
60. Inhibition of parental tumor colony formation by cells from a semi allogeneic mixed spleen cell reaction. Jones TL; Kennedy JC Transplantation; 1976 Aug; 22(2):176-83. PubMed ID: 968934 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]